Improving cancer immunotherapy by targeting the STATe of MDSCs

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  de Haas, Nienke ^a   de Koning, Coco ^a   Spilgies, Lisanne ^a   de Vries, I Jolanda M ^a   Hato, Stanleyson V ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drugs; immunotherapy; MDSCs; STAT signaling; tumor microenvironment

Indexed keywords

AMILORIDE; AXITINIB; BEVACIZUMAB; CALCIDIOL 1 MONOOXYGENASE; CIMETIDINE; CUCURBITACIN; CURCUMIN; DECITABINE; DOCETAXEL; ICARIIN; IPILIMUMAB; PACLITAXEL; ROSIGLITAZONE; SILDENAFIL; SORAFENIB; STAT PROTEIN; SUNITINIB; TADALAFIL; VEMURAFENIB;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MYELOID DERIVED SUPPRESSOR CELL; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

EID: 84982908724     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1196312     Document Type: Review

References (88)

1. C.Robert, J.Schachter, G.V.Long, A.Arance, J.J.Grob, L.Mortier, A.Daud, M.S.Carlino, C.McNeil, M.Lotem et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
2. A.Rotte, M.Bhandaru, Y.Zhou, K.J.McElwee. Immunotherapy of melanoma:present options and future promises. Cancer Metastasis Rev 2015; 34:115-28; PMID:25589384; http://dx.doi.org/10.1007/s10555-014-9542-0
3. J.C.Becker, M.H.Andersen, D.Schrama, P.Thor Straten. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013; 62:1137-48; PMID:23666510; http://dx.doi.org/10.1007/s00262-013-1434-6
4. S.Walter, T.Weinschenk, A.Stenzl, R.Zdrojowy, A.Pluzanska, C.Szczylik, M.Staehler, W.Brugger, P.Y.Dietrich, R.Mendrzyk et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
5. F.Arihara, E.Mizukoshi, M.Kitahara, Y.Takata, K.Arai, T.Yamashita, Y.Nakamoto, S.Kaneko. Increase in CD14+HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62:1421-30; PMID:23764929; http://dx.doi.org/10.1007/s00262-013-1447-1
6. R.R.Laborde, Y.Lin, M.P.Gustafson, P.A.Bulur, A.B.Dietz. Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo/neg) Cells):the gateway to improved responses. Front Immunol 2014; 5:147; PMID:24772111; http://dx.doi.org/10.3389/fimmu.2014.00147
7. K.N.Kodumudi, A.Weber, A.A.Sarnaik, S.Pilon-Thomas. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012; 189:5147-54; PMID:23100512; http://dx.doi.org/10.4049/jimmunol.1200274
8. C.Meyer, L.Cagnon, C.M.Costa-Nunes, P.Baumgaertner, N.Montandon, L.Leyvraz, O.Michielin, E.Romano, D.E.Speiser. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63:247-57; PMID:24357148; http://dx.doi.org/10.1007/s00262-013-1508-5
9. M.K.Srivastava, L.Zhu, M.Harris-White, U.K.Kar, M.Huang, M.F.Johnson, J.M.Lee, D.Elashoff, R.Strieter, S.Dubinett et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7:e40677; PMID:22815789; http://dx.doi.org/10.1371/journal.pone.0040677
10. J.K.Morales, M.Kmieciak, L.Graham, M.Feldmesser, H.D.Bear, M.H.Manjili. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 2009; 58:941-53; PMID:18979098; http://dx.doi.org/10.1007/s00262-008-0609-z
11. F.Shojaei, X.Wu, A.K.Malik, C.Zhong, M.E.Baldwin, S.Schanz, G.Fuh, H.P.Gerber, N.Ferrara. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25:911-20; PMID:17664940; http://dx.doi.org/10.1038/nbt1323
12. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
13. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
14. J.I.Youn, S.Nagaraj, M.Collazo, D.I.Gabrilovich. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
15. S.Solito, I.Marigo, L.Pinton, V.Damuzzo, S.Mandruzzato, V.Bronte. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469
16. C.A.Dumitru, K.Moses, S.Trellakis, S.Lang, S.Brandau. Neutrophils and granulocytic myeloid-derived suppressor cells:immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012; 61:1155-67; PMID:22692756; http://dx.doi.org/10.1007/s00262-012-1294-5
17. E.K.Vetsika, F.Koinis, M.Gioulbasani, D.Aggouraki, A.Koutoulaki, E.Skalidaki, D.Mavroudis, V.Georgoulias, A.Kotsakis. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res 2014; 2014:659294; PMID:25436215; http://dx.doi.org/10.1155/2014/659294
18. A.Martens, H.Zelba, C.Garbe, G.Pawelec, B.Weide. Monocytic myeloid-derived suppressor cells in advanced melanoma patients:Indirect impact on prognosis through inhibition of tumor-specific T-cell responses? Oncoimmunology 2014; 3:e27845; PMID:24800171
19. P.Sinha, V.K.Clements, S.K.Bunt, S.M.Albelda, S.Ostrand-Rosenberg. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83; PMID:17617589; http://dx.doi.org/10.4049/jimmunol.179.2.977
20. J.P.Marcoe, J.R.Lim, K.L.Schaubert, N.Fodil-Cornu, M.Matka, A.L.McCubbrey, A.R.Farr, S.M.Vidal, Y.Laouar. TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol 2012; 13:843-50; PMID:22863752; http://dx.doi.org/10.1038/ni.2388
21. A.H.Zea, P.C.Rodriguez, M.B.Atkins, C.Hernandez, S.Signoretti, J.Zabaleta, D.McDermott, D.Quiceno, A.Youmans, A.O'Neill et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients:a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8; PMID:15833831
22. M.K.Srivastava, P.Sinha, V.K.Clements, P.Rodriguez, S.Ostrand-Rosenberg. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77; PMID:20028852; http://dx.doi.org/10.1158/0008-5472.CAN-09-2587
23. A.Mazzoni, V.Bronte, A.Visintin, J.H.Spitzer, E.Apolloni, P.Serafini, P.Zanovello, D.M.Segal. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-95; PMID:11777962; http://dx.doi.org/10.4049/jimmunol.168.2.689
24. J.Schmielau, O.J.Finn. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-60; PMID:11406548
25. S.Nagaraj, K.Gupta, V.Pisarev, L.Kinarsky, S.Sherman, L.Kang, D.L.Herber, J.Schneck, D.I.Gabrilovich. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609
26. B.Molon, S.Ugel, F.Del Pozzo, C.Soldani, S.Zilio, D.Avella, A.De Palma, P.Mauri, A.Monegal, M.Rescigno et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956
27. B.Hoechst, L.A.Ormandy, M.Ballmaier, F.Lehner, C.Kruger, M.P.Manns, T.F.Greten, F.Korangy. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234-43; PMID:18485901; http://dx.doi.org/10.1053/j.gastro.2008.03.020
28. P.Serafini, S.Mgebroff, K.Noonan, I.Borrello. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; PMID:18593947; http://dx.doi.org/10.1158/0008-5472.CAN-07-6621
29. B.Huang, P.Y.Pan, Q.Li, A.I.Sato, D.E.Levy, J.Bromberg, C.M.Divino, S.H.Chen. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
30. J.J.O'Shea, D.M.Schwartz, A.V.Villarino, M.Gadina, I.B.McInnes, A.Laurence. The JAK-STAT pathway:impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66:311-28; PMID:25587654; http://dx.doi.org/10.1146/annurev-med-051113-024537
31. T.Condamine, D.I.Gabrilovich. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25; PMID:21067974; http://dx.doi.org/10.1016/j.it.2010.10.002
32. C.A.Corzo, M.J.Cotter, P.Cheng, F.Cheng, S.Kusmartsev, E.Sotomayor, T.Padhya, T.V.McCaffrey, J.C.McCaffrey, D.I.Gabrilovich. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; PMID:19380816; http://dx.doi.org/10.4049/jimmunol.0900092
33. D.Vasquez-Dunddel, F.Pan, Q.Zeng, M.Gorbounov, E.Albesiano, J.Fu, R.L.Blosser, A.J.Tam, T.Bruno, H.Zhang et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 123:1580-9; PMID:23454751; http://dx.doi.org/10.1172/JCI60083
34. P.Cheng, C.A.Corzo, N.Luetteke, B.Yu, S.Nagaraj, M.M.Bui, M.Ortiz, W.Nacken, C.Sorg, T.Vogl et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi.org/10.1084/jem.20080132
35. X.Chen, E.A.Eksioglu, J.Zhou, L.Zhang, J.Djeu, N.Fortenbery, P.Epling-Burnette, S.Van Bijnen, H.Dolstra, J.Cannon et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 2013; 123:4595-611; PMID:24216507; http://dx.doi.org/10.1172/JCI67580
36. L.M.Hix, J.Karavitis, M.W.Khan, Y.H.Shi, K.Khazaie, M.Zhang. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem 2013; 288:11676-88; PMID:23486482; http://dx.doi.org/10.1074/jbc.M112.441402
37. K.Movahedi, M.Guilliams, J.Van den Bossche, R.Van den Bergh, C.Gysemans, A.Beschin, P.De Baetselier, J.A.Van Ginderachter. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
38. J.D.Waight, C.Netherby, M.L.Hensen, A.Miller, Q.Hu, S.Liu, P.N.Bogner, M.R.Farren, K.P.Lee, K.Liu et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013; 123:4464-78; PMID:24091328; http://dx.doi.org/10.1172/JCI68189
39. V.Munera, P.J.Popovic, J.Bryk, J.Pribis, D.Caba, B.M.Matta, M.Zenati, J.B.Ochoa. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg 2010; 251:120-6; PMID:20032720; http://dx.doi.org/10.1097/SLA.0b013e3181bfda1c
40. P.Sinha, V.K.Clements, S.Ostrand-Rosenberg. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174:636-45; PMID:15634881; http://dx.doi.org/10.4049/jimmunol.174.2.636
41. F.Roth, A.C.De La Fuente, J.L.Vella, A.Zoso, L.Inverardi, P.Serafini. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012; 72:1373-83; PMID:22282665; http://dx.doi.org/10.1158/0008-5472.CAN-11-2772
42. S.V.Hato, A.Khong, I.J.de Vries, W.J.Lesterhuis. Molecular pathways:the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014; 20:2831-7; PMID:24879823; http://dx.doi.org/10.1158/1078-0432.CCR-13-3141
43. B.Schilling, A.Sucker, K.Griewank, F.Zhao, B.Weide, A.Gorgens, B.Giebel, D.Schadendorf, A.Paschen. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133:1653-63; PMID:23526263; http://dx.doi.org/10.1002/ijc.28168
44. B.Schilling, A.Paschen. Immunological consequences of selective BRAF inhibitors in malignant melanoma:neutralization of myeloid-derived suppressor cells. Oncoimmunology 2013; 2:e25218; PMID:24167759
45. P.Bhargava, M.O.Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors:current status. Curr Oncol Rep 2011; 13:103-11; PMID:21318618; http://dx.doi.org/10.1007/s11912-011-0154-3
46. H.Yuan, P.Cai, Q.Li, W.Wang, Y.Sun, Q.Xu, Y.Gu. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed Pharmacother 2014; 68:751-6; PMID:25081318; http://dx.doi.org/10.1016/j.biopha.2014.07.002
47. A.Bose, D.B.Lowe, A.Rao, W.J.Storkus. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22:236-43; PMID:22504156; http://dx.doi.org/10.1097/CMR.0b013e3283538293
48. M.Cao, Y.Xu, J.I.Youn, R.Cabrera, X.Zhang, D.Gabrilovich, D.R.Nelson, C.Liu. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest 2011; 91:598-608; PMID:21321535; http://dx.doi.org/10.1038/labinvest.2010.205
49. J.S.Ko, A.H.Zea, B.I.Rini, J.L.Ireland, P.Elson, P.Cohen, A.Golshayan, P.A.Rayman, L.Wood, J.Garcia et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
50. J.Finke, J.Ko, B.Rini, P.Rayman, J.Ireland, P.Cohen. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11:856-61; PMID:21315783; http://dx.doi.org/10.1016/j.intimp.2011.01.030
51. J.S.Ko, P.Rayman, J.Ireland, S.Swaidani, G.Li, K.D.Bunting, B.Rini, J.H.Finke, P.A.Cohen. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278
52. D.J.Panka, Q.Liu, A.K.Geissler, J.W.Mier. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer 2013; 12:17; PMID:23497256; http://dx.doi.org/10.1186/1476-4598-12-17
53. T.Osada, G.Chong, R.Tansik, T.Hong, N.Spector, R.Kumar, H.I.Hurwitz, I.Dev, A.B.Nixon, H.K.Lyerly et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57:1115-24; PMID:18193223; http://dx.doi.org/10.1007/s00262-007-0441-x
54. S.K.Bunt, A.M.Mohr, J.M.Bailey, P.M.Grandgenett, M.A.Hollingsworth. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol Immunother 2013; 62:225-36; PMID:22864396; http://dx.doi.org/10.1007/s00262-012-1324-3
55. Y.Zheng, M.Xu, X.Li, J.Jia, K.Fan, G.Lai. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol 2013; 54:74-83; PMID:23220070; http://dx.doi.org/10.1016/j.molimm.2012.10.035
56. Y.Pico de Coana, I.Poschke, G.Gentilcore, Y.Mao, M.Nystrom, J.Hansson, G.V.Masucci, R.Kiessling. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1:158-62; PMID:24777678; http://dx.doi.org/10.1158/2326-6066.CIR-13-0016
57. A.A.Tarhini, H.Edington, L.H.Butterfield, Y.Lin, Y.Shuai, H.Tawbi, C.Sander, Y.Yin, M.Holtzman, J.Johnson et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014; 9:e87705; PMID:24498358; http://dx.doi.org/10.1371/journal.pone.0087705
58. S.Ugel, F.Delpozzo, G.Desantis, F.Papalini, F.Simonato, N.Sonda, S.Zilio, V.Bronte. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470-81; PMID:19616475; http://dx.doi.org/10.1016/j.coph.2009.06.014
59. P.Serafini, K.Meckel, M.Kelso, K.Noonan, J.Califano, W.Koch, L.Dolcetti, V.Bronte, I.Borrello. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; http://dx.doi.org/10.1084/jem.20061104
60. C.Meyer, A.Sevko, M.Ramacher, A.V.Bazhin, C.S.Falk, W.Osen, I.Borrello, M.Kato, D.Schadendorf, M.Baniyash et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 2011; 108:17111-6; PMID:21969559; http://dx.doi.org/10.1073/pnas.1108121108
61. D.T.Weed, J.L.Vella, I.M.Reis, A.C.De la Fuente, C.Gomez, Z.Sargi, R.Nazarian, J.Califano, I.Borrello, P.Serafini. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:39-48; PMID:25320361; http://dx.doi.org/10.1158/1078-0432.CCR-14-1711
62. J.A.Califano, Z.Khan, K.A.Noonan, L.Rudraraju, Z.Zhang, H.Wang, S.Goodman, C.G.Gourin, P.K.Ha, C.Fakhry et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:30-8; PMID:25564570; http://dx.doi.org/10.1158/1078-0432.CCR-14-1716
63. K.A.Noonan, N.Ghosh, L.Rudraraju, M.Bui, I.Borrello. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res 2014; 2:725-31; PMID:24878583; http://dx.doi.org/10.1158/2326-6066.CIR-13-0213
64. D.Salvemini, S.F.Kim, V.Mollace. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology:relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol 2013; 304:R473-87; PMID:23389111; http://dx.doi.org/10.1152/ajpregu.00355.2012
65. N.Obermajer, R.Muthuswamy, J.Lesnock, R.P.Edwards, P.Kalinski. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118:5498-505; PMID:21972293; http://dx.doi.org/10.1182/blood-2011-07-365825
66. F.Chalmin, S.Ladoire, G.Mignot, J.Vincent, M.Bruchard, J.P.Remy-Martin, W.Boireau, A.Rouleau, B.Simon, D.Lanneau et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120:457-71; PMID:20093776; http://dx.doi.org/10.1172/JCI40483DS1
67. J.Zhou, J.Wu, X.Chen, N.Fortenbery, E.Eksioglu, K.N.Kodumudi, E.B.Pk, J.Dong, J.Y.Djeu, S.Wei. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol 2011; 11:890-8; PMID:21244860; http://dx.doi.org/10.1016/j.intimp.2011.01.007
68. I.Daurkin, E.Eruslanov, J.Vieweg, S.Kusmartsev. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunother 2010; 59:697-706; PMID:19882154; http://dx.doi.org/10.1007/s00262-009-0786-4
69. J.M.Lee, J.H.Seo, Y.J.Kim, Y.S.Kim, H.J.Ko, C.Y.Kang. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2012; 131:741-51; PMID:21898392; http://dx.doi.org/10.1002/ijc.26411
70. S.Kusmartsev, Z.Su, A.Heiser, J.Dannull, E.Eruslanov, H.Kubler, D.Yancey, P.Dahm, J.Vieweg. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008; 14:8270-8; PMID:19088044; http://dx.doi.org/10.1158/1078-0432.CCR-08-0165
71. C.Iclozan, S.Antonia, A.Chiappori, D.T.Chen, D.Gabrilovich. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909-18; PMID:23589106; http://dx.doi.org/10.1007/s00262-013-1396-8
72. Y.Nefedova, M.Fishman, S.Sherman, X.Wang, A.A.Beg, D.I.Gabrilovich. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007; 67:11021-8; PMID:18006848; http://dx.doi.org/10.1158/0008-5472.CAN-07-2593
73. T.Michels, G.V.Shurin, H.Naiditch, A.Sevko, V.Umansky, M.R.Shurin. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 2012; 9:292-300; PMID:22283566; http://dx.doi.org/10.3109/1547691X.2011.642418
74. L.W.Pfannenstiel, S.S.Lam, L.A.Emens, E.M.Jaffee, T.D.Armstrong. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010; 263:79-87; PMID:20346445; http://dx.doi.org/10.1016/j.cellimm.2010.03.001
75. A.Sevko, T.Michels, M.Vrohlings, L.Umansky, P.Beckhove, M.Kato, G.V.Shurin, M.R.Shurin, V.Umansky. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol 2013; 190:2464-71; PMID:23359505; http://dx.doi.org/10.4049/jimmunol.1202781
76. K.N.Kodumudi, K.Woan, D.L.Gilvary, E.Sahakian, S.Wei, J.Y.Djeu. A novel chemoimmunomodulating property of docetaxel:suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94; PMID:20702612; http://dx.doi.org/10.1158/1078-0432.CCR-10-0733
77. Y.Nefedova, S.Nagaraj, A.Rosenbauer, C.Muro-Cacho, S.M.Sebti, D.I.Gabrilovich. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65:9525-35; PMID:16230418; http://dx.doi.org/10.1158/0008-5472.CAN-05-0529
78. P.Lu, B.Yu, J.Xu. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother Radiopharm 2012; 27:495-503; PMID:22746287; http://dx.doi.org/10.1089/cbr.2012.1219
79. V.Kumar, P.Cheng, T.Condamine, S.Mony, L.R.Languino, J.C.McCaffrey, N.Hockstein, M.Guarino, G.Masters, E.Penman et al. CD45 Phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 2016; 44:303-15; PMID:26885857; http://dx.doi.org/10.1016/j.immuni.2016.01.014
80. S.P.Tu, H.Jin, J.D.Shi, L.M.Zhu, Y.Suo, G.Lu, A.Liu, T.C.Wang, C.S.Yang. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 2012; 5:205-15; PMID:22030090; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0247
81. M.R.Young, M.A.Wright, K.Vellody, D.M.Lathers. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. Int J Immunopharmacol 1999; 21:675-88; PMID:12609462; http://dx.doi.org/10.1016/S0192-0561(99)00044-2
82. J.S.Kulbersh, T.A.Day, M.B.Gillespie, M.R.Young. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol Head Neck Surg 2009; 140:235-40; PMID:19201295; http://dx.doi.org/10.1016/j.otohns.2008.11.011
83. J.E.Walsh, A.M.Clark, T.A.Day, M.B.Gillespie, M.R.Young. Use of α,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 2010; 71:659-65; PMID:20438786; http://dx.doi.org/10.1016/j.humimm.2010.04.008
84. M.Di Maio, C.Gallo, N.B.Leighl, M.C.Piccirillo, G.Daniele, F.Nuzzo, C.Gridelli, V.Gebbia, F.Ciardiello, S.De Placido et al. Symptomatic toxicities experienced during anticancer treatment:agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33:910-5; PMID:25624439; http://dx.doi.org/10.1200/JCO.2014.57.9334
85. N.C.Miltenburg, W.Boogerd. Chemotherapy-induced neuropathy:A comprehensive survey. Cancer Treat Rev 2014; 40:872-82; PMID:24830939; http://dx.doi.org/10.1016/j.ctrv.2014.04.004
86. L.Gelao, C.Criscitiello, A.Esposito, A.Goldhirsch, G.Curigliano. Immune checkpoint blockade in cancer treatment:a double-edged sword cross-targeting the host as an “innocent bystander”. Toxins (Basel) 2014; 6:914-33; PMID:24594636; http://dx.doi.org/10.3390/toxins6030914
87. K.Nishimura, J.Saegusa, F.Matsuki, K.Akashi, G.Kageyama, A.Morinobu. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice. Arthritis Rheumatol 2015; 67:893-902; PMID:25545152; http://dx.doi.org/10.1002/art.39007
88. S.K.Maenhout, S.Du Four, J.Corthals, B.Neyns, K.Thielemans, J.L.Aerts. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget 2014; 5:6801-15; PMID:25149535